The Riverside Company’s investing in Belgian pharmaceutical distribution group Alter Pharma


Alter Pharma NV, a Belgian pharmaceutical group, received an investment from The Riverside Company.

Belfius Bank, ING Belgium and NIBC Bank provided financing for the transaction, whose amount was not disclosed.

Alter Pharma’s products serve a wide range of therapeutic areas, including oncology, gastroenterology, pain, cardiology, neurology and others to follow.

Allen & Overy, Ernst & Young, IQVIA, Alix Partners and NDA Group advised Riverside on the deal.

Jefferies acted as exclusive financial adviser to Alter Pharma.

Eubelius provided legal advice to Alter Pharma with a team led by Erwin Destuyver (picture) and Michiel Stuyts. Jan Bocken and Marieke Van Nieuwenborgh provided competition law advice.

Involved fees earner: Erwin Destuyver – Eubelius; Michiel Stuyts – Eubelius; Jan Bocken – Eubelius; Marieke Van Nieuwenborgh – Eubelius;

Law Firms: Eubelius;

Clients: Alter Pharma NV;